Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA

Articles by Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?

ByApril W. Armstrong, MD, MPH, Professor and Chief of Dermatology, University of California, Los Angeles,Kassim Rahawi, PharmD, Sanofi, Cambridge, USA,Wendell Valdecantos, MD, Sanofi, Cambridge, USA,Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA

October 22nd 2024

Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.

Latest Updated Articles

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?
Published: October 22nd 2024 | Updated:

Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA

Articles by Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?

Latest Updated Articles

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN